Skip to content

Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch

Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04588532
Enrollment
24
Registered
2020-10-19
Start date
2020-10-01
Completion date
2021-06-01
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Itch

Brief summary

With this experiment, the experimenter wish to asses if substance BAM8-22 (Bovine Adrenal Medulla) induce non-histaminergic itch.

Detailed description

With this experiment, the experimenter wish to establish if the substance BAM8-22 (Bovine Adrenal Medulla) induce a non-histaminergic itch by using the antihistamine Doxepin. The experimenter will also compare itch and the response to antihistamine of BAM8-22, histamine and cowhage.

Interventions

DRUGBAM8-22

Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

DRUGHistamine

histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm

Sponsors

Aalborg University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy men and women * 18-60 years * Speak and understand English

Exclusion criteria

* Pregnancy or lactation * Drug addiction defined as any use of cannabis, opioids or other drugs * Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.) * Moles, wounds, scars or tattoos in the area to be treated or tested * Lack of ability to cooperate • * Current use of medications that may affect the trial such as antihistamines and pain killers. * Skin diseases * Consumption of alcohol or painkillers 24 hours before the study days and between these - Acute or chronic pain • * Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)

Design outcomes

Primary

MeasureTime frameDescription
itch ratingchange from baseline, up to 10 minutes after the first sessionthe subject will rate the itch for 10 minutes by using a visual analog scale (VAS) on a tablet. this scale goes from 0 to 100. 0 indicates no itch and 100 indicates worst imaginable itch
superficial blood perfusionchange from baseline, up to 10 minutes after the first sessionis measured by a speckle contrast imager (FLPI, Moor Instruments, England)
Warm Detection Threshold, and Heat Pain thresholdchange from baseline, up to 10 minutes after the first sessionthe tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
Cold Detection Threshold and Cold Pain thresholdchange from baseline, up to 10 minutes after the first sessionthe tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
Pain supra-threshold heat Stimulichange from baseline, up to 10 minutes after the first sessionthe tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device
hyperknesis (abnormal pruriceptive state)change from baseline, up to 10 minutes after the first sessionis measured by using a mildly pruritic, non-painful von Frey filaments of a predetermined intensity (generally 5-30 milliNewton of force)
mechanical pain threshold and sensitivitychange from baseline, up to 10 minutes after the first sessionis performed using a pin-prick set (Aalborg University). The set consists of 8 needles each having a diameter of 0,6 mm and different force applications

Secondary

MeasureTime frameDescription
pain ratingchange from baseline, up to 10 minutes after the first sessionthe subject will rate the pain for 10 minutes by using a visual analog scale (VAS) on a tablet. this scale goes from 0 to 100. 0 indicates no pain and 100 indicates worst imaginable pain

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026